Voluntary nationwide recall: Clonazepam (Endo – July)
Sep. 2024Pharmacy Updates
Endo USA Inc. has recalled one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg. Clonazepam is used to treat panic disorder and certain seizures.
This product is being recalled because the cartons of some packs show the product strength as 0.125 mg, not 0.25 mg, due to an error at a third-party packager. The blister strips inside the product pack reflect the correct strength of 0.25 mg.
Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.
As of July 16, there had been no reports of adverse events related to this recall.
To learn more about this recall:
- Call Inmar Inc. at 1-877-890-0765. Help is available Monday through Friday from 9 a.m. to 5 p.m. ET.
- Visit the FDA website.
Recent Announcements
The importance of PRD forms for complex patients and staying updated on changes
Personal representative designation (PRD) forms are critical to the care process for patients and providers alike. Not only do PRDs support accurate, efficient, and compliant patient care—they also streamline administrative processes.Aug. 2025Important Notices
Important announcement: UPMC Health Plan retires MP.PA.147
This communication is in regards to UPMC Health Plan Policy MP.PA.147 – Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older. UPMC Health Plan previously communicated that the prior authorization requirement under this policy would be paused until Sept. 1, 2025. However, policy MP.PA.147 has been retired, and this policy will no longer be implemented or active.Aug. 2025Important Notices
CMS expands Medicare Advantage RADV audits to all eligible plans
On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a substantial expansion of its Risk Adjustment Data Validation (RADV) audit program for Medicare Advantage plans.Aug. 2025What's New